The high contrast of modern oncological PET tracers [e.g., 18F-FDG, somatostatin receptor (SSTR) and PSMA ligands, 18F-DOPA, 18F-MFBG (172)] permits straightforward three-dimensional segmentation of lesions; by segmenting all lesions, the total tumor burden can then be obtained. This evidence concerns the gene FOLH1 and neoplasm.